258 related articles for article (PubMed ID: 32344322)
21. Frequency matters: comparison of drug resistance mutation detection by Sanger and next-generation sequencing in HIV-1.
Balakrishna S; Loosli T; Zaheri M; Frischknecht P; Huber M; Kusejko K; Yerly S; Leuzinger K; Perreau M; Ramette A; Wymant C; Fraser C; Kellam P; Gall A; Hirsch HH; Stoeckle M; Rauch A; Cavassini M; Bernasconi E; Notter J; Calmy A; Günthard HF; Metzner KJ; Kouyos RD
J Antimicrob Chemother; 2023 Mar; 78(3):656-664. PubMed ID: 36738248
[TBL] [Abstract][Full Text] [Related]
22. Performance of the Applied Biosystems HIV-1 Genotyping Kit with Integrase.
Moore HP; Palumbo PJ; Notarte KI; Fogel JM; Cummings V; Gamble T; Del Rio C; Batey DS; Mayer KH; Farley JE; Remien RH; Beyrer C; Hudelson SE; Eshleman SH;
J Clin Microbiol; 2024 Jun; 62(6):e0013624. PubMed ID: 38727213
[TBL] [Abstract][Full Text] [Related]
23. Clinical evaluation of an in-house human immunodeficiency virus (HIV) genotyping assay for the detection of drug resistance mutations in HIV-1 infected patients in Singapore.
Chew KK; Ng KY; Khong WX; Kaur P; Yap JK; Chua A; Tan MT; Koh YL; Thoon KC; Leo YS; Ng OT
Ann Acad Med Singap; 2012 Dec; 41(12):553-8. PubMed ID: 23303111
[TBL] [Abstract][Full Text] [Related]
24. Distinctive Drug-resistant Mutation Profiles and Interpretations of HIV-1 Proviral DNA Revealed by Deep Sequencing in Reverse Transcriptase.
Yin QQ; Li ZP; Zhao H; Pan D; Wang Y; Xu WS; Xing H; Feng Y; Jiang SB; Shao YM; Ma LY
Biomed Environ Sci; 2016 Apr; 29(4):239-47. PubMed ID: 27241734
[TBL] [Abstract][Full Text] [Related]
25. Cost-efficient HIV-1 drug resistance surveillance using multiplexed high-throughput amplicon sequencing: implications for use in low- and middle-income countries.
Ekici H; Rao SD; Sönnerborg A; Ramprasad VL; Gupta R; Neogi U
J Antimicrob Chemother; 2014 Dec; 69(12):3349-55. PubMed ID: 25085657
[TBL] [Abstract][Full Text] [Related]
26. Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq.
Dudley DM; Bailey AL; Mehta SH; Hughes AL; Kirk GD; Westergaard RP; O'Connor DH
Retrovirology; 2014 Dec; 11():122. PubMed ID: 25533166
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of Automatic Analysis of Ultradeep Pyrosequencing Raw Data to Determine Percentages of HIV Resistance Mutations in Patients Followed-Up in Hospital.
Bellecave P; Recordon-Pinson P; Fleury H
AIDS Res Hum Retroviruses; 2016 Jan; 32(1):85-92. PubMed ID: 26529549
[TBL] [Abstract][Full Text] [Related]
28. Investigation of drug resistance against protease, reverse transcriptase, and integrase inhibitors by next-generation sequencing in HIV-positive patients.
Tekin D; Gokengin D; Onay H; Erensoy S; Sertoz R
J Med Virol; 2021 Jun; 93(6):3627-3633. PubMed ID: 33026651
[TBL] [Abstract][Full Text] [Related]
29. An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing.
Simen BB; Braverman MS; Abbate I; Aerssens J; Bidet Y; Bouchez O; Gabriel C; Izopet J; Kessler HH; Stelzl E; Di Giallonardo F; Schlapbach R; Radonic A; Paredes R; Recordon-Pinson P; Sakwa J; St John EP; Schmitz-Agheguian GG; Metzner KJ; Däumer MP;
J Virol Methods; 2014 Aug; 204():31-7. PubMed ID: 24731928
[TBL] [Abstract][Full Text] [Related]
30. Comparison of HIV-1 drug-resistance genotyping by ultra-deep sequencing and sanger sequencing using clinical samples.
Trabaud MA; Icard V; Ramière C; Tardy JC; Scholtes C; André P
J Med Virol; 2017 Nov; 89(11):1912-1919. PubMed ID: 28590068
[TBL] [Abstract][Full Text] [Related]
31. Performance of Celera RUO integrase resistance assay across multiple HIV-1 subtypes.
Wallis CL; Viana RV; Saravanan S; Silva de Jesus C; Zeh C; Halvas EK; Mellors JW
J Virol Methods; 2017 Mar; 241():41-45. PubMed ID: 27993614
[TBL] [Abstract][Full Text] [Related]
32. Development and Validation of a Template-Independent Next-Generation Sequencing Assay for Detecting Low-Level Resistance-Associated Variants of Hepatitis C Virus.
Wei B; Kang J; Kibukawa M; Chen L; Qiu P; Lahser F; Marton M; Levitan D
J Mol Diagn; 2016 Sep; 18(5):643-656. PubMed ID: 27393904
[TBL] [Abstract][Full Text] [Related]
33. A MiSeq-HyDRA platform for enhanced HIV drug resistance genotyping and surveillance.
Taylor T; Lee ER; Nykoluk M; Enns E; Liang B; Capina R; Gauthier MK; Domselaar GV; Sandstrom P; Brooks J; Ji H
Sci Rep; 2019 Jun; 9(1):8970. PubMed ID: 31222149
[TBL] [Abstract][Full Text] [Related]
34. Ultradeep sequencing of B and non-B HIV-1 subtypes: Viral diversity and drug resistance mutations before and after one month of antiretroviral therapy in naive patients.
Epaulard O; Signori-Schmuck A; Larrat S; Kulkarni O; Blum MG; Fusillier K; Blanc M; Leclercq P; François O; Morand P
J Clin Virol; 2017 Oct; 95():13-19. PubMed ID: 28830014
[TBL] [Abstract][Full Text] [Related]
35. Comparison between next-generation and Sanger-based sequencing for the detection of transmitted drug-resistance mutations among recently infected HIV-1 patients in Israel, 2000-2014.
Moscona R; Ram D; Wax M; Bucris E; Levy I; Mendelson E; Mor O
J Int AIDS Soc; 2017 Aug; 20(1):21846. PubMed ID: 28799325
[TBL] [Abstract][Full Text] [Related]
36. HIV-1 Drug Resistance Assay Using Ion Torrent Next Generation Sequencing and On-Instrument End-to-End Analysis Software.
Pyne MT; Simmon KE; Mallory MA; Hymas WC; Stevenson J; Barker AP; Hillyard DR
J Clin Microbiol; 2022 Jul; 60(7):e0025322. PubMed ID: 35699434
[TBL] [Abstract][Full Text] [Related]
37. Multimethod Longitudinal HIV Drug Resistance Analysis in Antiretroviral-Therapy-Naive Patients.
Nanfack AJ; Redd AD; Bimela JS; Ncham G; Achem E; Banin AN; Kirkpatrick AR; Porcella SF; Agyingi LA; Meli J; Colizzi V; Nádas A; Gorny MK; Nyambi PN; Quinn TC; Duerr R
J Clin Microbiol; 2017 Sep; 55(9):2785-2800. PubMed ID: 28659324
[TBL] [Abstract][Full Text] [Related]
38. Long-Range HIV Genotyping Using Viral RNA and Proviral DNA for Analysis of HIV Drug Resistance and HIV Clustering.
Novitsky V; Zahralban-Steele M; McLane MF; Moyo S; van Widenfelt E; Gaseitsiwe S; Makhema J; Essex M
J Clin Microbiol; 2015 Aug; 53(8):2581-92. PubMed ID: 26041893
[TBL] [Abstract][Full Text] [Related]
39. Transmitted HIV-1 drug resistance in a large international cohort using next-generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study.
Baxter JD; Dunn D; Tostevin A; Marvig RL; Bennedbaek M; Cozzi-Lepri A; Sharma S; Kozal MJ; Gompels M; Pinto AN; Lundgren J;
HIV Med; 2021 May; 22(5):360-371. PubMed ID: 33369017
[TBL] [Abstract][Full Text] [Related]
40. HIV-1 Drug Resistance Genotyping in Resource Limited Settings: Current and Future Perspectives in Sequencing Technologies.
Manyana S; Gounder L; Pillay M; Manasa J; Naidoo K; Chimukangara B
Viruses; 2021 Jun; 13(6):. PubMed ID: 34208165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
